Danny Bega

Grants

Grants per year 2014 2015 2019 2021 2028

• 13 Active
• 52 Finished

Grants per year

Search results

• Active

  2024 HDSA Center of Excellence Program

  Bega, D. (PD/PI)

  Huntington's Disease Society of America

  1/1/24 → 12/31/24

  Project: Research project

• Parkinson’s Foundation FY24 Center of Excellence Award

  Simuni, T. (PD/PI) & Bega, D. (Co-Investigator)

  Parkinson's Foundation, Inc.

  12/1/23 → 11/30/24

  Project: Research project

• Enroll-HD Study Site Agreement, dated Apr 23, 2015 (RecID A-9045) – Enroll-HD Study Price Increase

  Bega, D. (PD/PI)

  CHDI Foundation, Inc.

  7/1/23 → 6/30/28

  Project: Research project

• (OE) Prot# BN42489: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Biomakers, and Efficacy of Tominersen in Individuals with Prodromal and Early Manifest Hungtington's Disease

  Bega, D. (PD/PI)

  INC Research, LLC, Genentech, Inc

  3/6/23 → 11/30/26

  Project: Research project

• Prot# 718-CNP-202: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Parkinson's Disease Cognitive Impairment

  Bega, D. (PD/PI)

  Parexel, Sage Therapeutics, Inc.

  2/28/23 → 2/28/26

  Project: Research project

• Prot# 718-CNP-202: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Parkinson's Disease Cognitive Impairment

  Bega, D. (PD/PI)

  Parexel, Sage Therapeutics, Inc.

  2/28/23 → 2/28/26

  Project: Research project

• Prot#718-CIH-201: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants with Huntington's Disease

  Bega, D. (PD/PI)

  Parexel, Sage Therapeutics, Inc.

  4/11/22 → 4/11/25

  Project: Research project

• The Edmond J. Safra Fellowship in Movement Disorders - Class of 2025

  Simuni, T. (PD/PI), Bega, D. (Other), Goldman, J. G. (Other), Krainc, D. (Other) & Wu, A. D. (Other)

  Michael J. Fox Foundation for Parkinson's Research

  4/1/22 → 6/30/25

  Project: Research project

• Prot#UX701-CL301: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Seamless, Adaptive, Safety, Dose-Finding, and Phase 3 Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease

  Bega, D. (PD/PI)

  PPD Investigator Services, LLC, Ultragenyx Pharmaceutical Inc.

  5/27/21 → 5/31/25

  Project: Research project

• Prot#PL101-HD301: Prilenia Therapeutics / A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease (PROOF-HD)

  Bega, D. (PD/PI)

  HSG Clinical Research, Inc., Prilenia Neurotherapeutics Ltd

  11/24/20 → 11/24/24

  Project: Research project

• Prot# UX701-CL001 Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects with Wilson Disease

  Bega, D. (PD/PI)

  Ultragenyx Pharmaceutical Inc.

  8/18/20 → 10/31/24

  Project: Research project

• NBI-98854-HD3005: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease

  Bega, D. (PD/PI)

  Huntington Study Group Ltd., Neurocrine Biosciences, Inc.

  1/13/20 → 1/31/26

  Project: Research project

• Prot#WTX101-301: A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older with an Extension Phase of up to 60 Mont

  Bega, D. (PD/PI)

  Alexion Pharmaceuticals, Inc, Wilson Therapeutics AB

  3/1/18 → 12/31/24

  Project: Research project